Skip to main content
DSGN
NASDAQ Life Sciences

Design Therapeutics 10-Q: Q3 Loss $20.3M, $208.6M Cash, ATM Upsized to $200M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$10.63
Mkt Cap
$665.243M
52W Low
$6.16
52W High
$17.25
52W Position info
73% above low
Off High info
38% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

DSGN sits 73% above its 52-week low of $6.16.

Summary

Design Therapeutics' Q3 10-Q confirms the $20.3 million quarterly loss and $208.6 million cash position, and discloses it sold 3.1 million ATM shares for $37.1 million net while moving to raise the ATM ceiling to $200 million.


Key Events · Earnings and Guidance · DSGN

  • Q3 Loss Widens to $20.3M

    Net loss was $20.3 million, or $0.32 per share, versus $17.0 million ($0.30) a year earlier; R&D rose to $16.9 million from $14.6 million.

  • ATM Upsized to $200M

    Design will file a prospectus supplement to raise the ATM Program ceiling from $100.0 million to $200.0 million, expanding the dilution overhang.

  • 3.1M ATM Shares Already Sold

    3,140,522 shares were sold under the ATM in the nine months to September 30, 2026 for about $37.1 million net; $36.4 million remained available before the increase.

  • Cash Covers More Than 12 Months

    Cash, equivalents and investments totaled $208.6 million at September 30, 2026, down $11.2 million from $219.8 million at December 31, 2025.


Analysis · DSGN · Life Sciences

The quarterly numbers match this morning's 8-K, but the 10-Q carries financing detail the 8-K did not. Design has already sold 3,140,522 shares under its ATM in 2026 for roughly $37.1 million net, and it will file a prospectus supplement to raise the ATM ceiling from $100 million to $200 million. With $208.6 million of cash and investments and a $58.1 million nine-month operating loss, the balance sheet funds operations for more than 12 months, but the enlarged ATM is a standing dilution overhang on top of 17.8 million options already outstanding. The clinical timeline is the swing factor: 12-week RESTORE-FA data for DT-216P2 has slipped to Q1 2027, with registrational plans due in Q4 2026.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DSGN was trading at $10.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $665.2M. The 52-week trading range was $6.16 to $17.25. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DSGN - Latest Insights

DSGN
Aug 03, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.12
Real-time Price: $9.02 info
Change: -$3.10 (-26%) info
Market Cap: $577.607M info
DSGN
Aug 03, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $12.12
Real-time Price: $9.02 info
Change: -$3.10 (-26%) info
Market Cap: $577.607M info
DSGN
May 18, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $18.33
Real-time Price: $9.02 info
Change: -$9.31 (-51%) info
Market Cap: $577.607M info
DSGN
May 18, 2026, 7:04 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $17.00
Real-time Price: $9.02 info
Change: -$7.98 (-47%) info
Market Cap: $577.607M info
DSGN
Apr 28, 2026, 4:13 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $12.81
Real-time Price: $9.02 info
Change: -$3.79 (-30%) info
Market Cap: $577.607M info